16 results about "Dimethylglycine" patented technology

The application discloses a storage-stable methylglycine-N,N-diacetic acid trialkali salt composition and a preparation method and application thereof, which comprises methylglycine-N,N-diacetic acid trialkali salt, N,N-dimethylglycine metal salt, sulfite and water. The composition can be used for storing and / or stabilizing transportation of methylglycine-N,N-diacetic acid trialkali salt, improving the stability of the metal ion chelating ability of the composition product, especially the stability of the chelating ability of calcium ions and magnesium ions, and the composition product can be stably applied to the fields of daily washing, water softening and sewage treatment.

This invention discloses a apigenin-betaine compound and its preparation method. The compound uses apigenin (Api) as its core, with -O-(CH2) at the 7', 4', and / or 5-position hydroxyl groups. n -N + (CH3)2-CH2COO ‑ Fragment substitution (n=2~12, x=1~3) forms an internal salt-type zwitterionic structure. In preparation, apigenin is first reacted with bromool Br(CH2). n A mitsunobu reaction was performed on OH under triphenylphosphine / dialkyl azodicarbonate conditions to obtain mono / polysubstituted bromoalkoxylated apigenin; subsequently, nucleophilic substitution with N,N-dimethylglycine under alkaline conditions yielded the target product. This structure, possessing both a tunable alkyl chain and a betaine cation / anion pair, significantly enhances the solubility and hydration capacity of apigenin in aqueous / alcoholic media, strengthens its affinity and stability for biomembranes, thereby improving in vivo absorption and distribution and potentially maintaining its antioxidant and anti-inflammatory activities. The method is mild, with a wide solvent and temperature range, suitable for scale-up and formulation applications.

The application belongs to the technical field of photoinitiators and preparation methods, and particularly relates to a preparation method of a macromolecular photoinitiator. The macromolecular photoinitiator is prepared from glycidyl methacrylate, methyl methacrylate, butyl acrylate, hydroxyethyl acrylate, 4-benzoylbenzoic acid, 2-carboxythioxanthone, N,N-dimethylglycine, monomethoxypolyethylene glycol, monohydroxypolycaprolactone and methacrylic acid. In the preparation, a tetra-acrylate polymer containing an epoxy group and a hydroxyl group is first prepared, and then double photoinitiation structure grafting, tertiary amine structure grafting, segment grafting and epoxy closure are sequentially performed, and the feeding amount of each stage is corrected through the initial epoxy value, the first residual epoxy value and the second residual epoxy value. The method connects the benzophenone structure, the thioxanthone structure and the tertiary amine structure to the same polymer molecular chain, reduces the content of unreacted small molecules and the migration and precipitation amount, improves the photocuring gel rate and shortens the surface drying time.

The invention discloses a metabolic marker for diagnosing lung function grading in a stable phase of chronic obstructive pulmonary disease and application of the metabolic marker. According to the invention, in a training set, the lysophosphatidylcholine (17: 0 / 0: 0) is combined with the dimethylglycine or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the 5-hydroxyindoleacetic acid or the lysophosphatidylcholine (17: 0 / 0: 0), and the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0). The combination of the L-pyroglutamic acid and the 5-hydroxyindoleacetic acid has excellent diagnosis efficiency in diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the chronic obstructive pulmonary disease in the stable phase; further, verification results in a verification set show that the four combined metabolic markers have excellent accuracy in combined diagnosis and distinguishing of patients with the lung functions of the chronic obstructive pulmonary disease at the 1-2 level and the 3-4 level in the stable phase. Therefore, the four combined metabolic markers have the prospect of being developed into a kit for diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the stable-phase chronic obstructive pulmonary disease.

The invention provides a urine metabolism marker combination for distinguishing kidney benign diseases and kidney cancer and application of the urine metabolism marker combination, and belongs to the technical field of biomarkers. The urine metabolism marker combination for distinguishing the kidney benign disease from the kidney cancer comprises at least two of the following components: (S)-2-piperidine-6-carboxylic acid, 2 '-deoxyguanosine, 3-hydroxybutyric acid, 6-aminocaproic acid, glycyl-L-proline, glycyl-gamma-aminobutyric acid, L-cysteine sulfinic acid and N, N-dimethyl formamide. The amino acid sequence is shown in the specification, and the amino acid sequence is shown in the specification. The amino acid sequence is shown in the specification, namely, N, N-dimethyl glycine, N-acetyl-L-glutamic acid, L-methionine-L-aspartic acid, 2-oxoglutaric acid and glycine chenodeoxycholic acid. Model construction and verification analysis show that the AUC values of diagnosis models constructed by combining different quantities of metabolite markers are all greater than 0.8, the sensitivity is greater than 0.7, and the specificity is greater than 0.7. Therefore, based on the urine metabolism marker combination screened by the invention, the kidney benign disease and the kidney cancer can be efficiently and accurately distinguished.

The invention discloses a biomarker combination for evaluating the occurrence risk of liver cancer microvascular invasion and application of the biomarker combination. The biomarker combination is prepared from V2FC, H2FC, N, N-dimethylglycine, H1FC, lactic acid, creatine and pyruvic acid. The biomarker combination provided by the invention can be applied to preparation of a product for evaluating the risk of occurrence of liver cancer microvascular invasion, a liver cancer-MVI prediction model constructed based on the biomarker combination provided by the invention can rapidly and accurately predict the risk of occurrence of MVI, preoperative accurate evaluation of MVI is facilitated, and the risk of occurrence of liver cancer microvascular invasion is reduced. The personalized treatment of the liver cancer patient is realized, and the prognosis of the liver cancer patient is improved.

The application provides a method for preparing sodium N,N-dimethylglycinate. The method comprises the following steps: (1) adding a sodium chloroacetate solution into a dimethylamine solution and reacting to obtain a reaction solution; wherein the pH of the reaction is controlled to be greater than 10.5 by adding alkali before or during the reaction; (2) mixing the reaction solution with hydrochloric acid after deamination treatment to obtain a solution containing N,N-dimethylglycinate; (3) reacting the solution containing N,N-dimethylglycinate with sodium hydroxide after impurity removal, solvent crystallization and drying to obtain a sodium N,N-dimethylglycinate product. The method can obtain sodium N,N-dimethylglycinate with high purity, high yield and good stability, and by controlling the drying temperature of the wet product of sodium N,N-dimethylglycinate, the sodium N,N-dimethylglycinate hydrate with good stability can be obtained.

This invention relates to the field of livestock and poultry feed preparation technology, and provides a meat quality improving livestock and poultry feed containing sodium dimethylglycinate and its preparation method, including a basal diet and meat quality improving functional particles dispersed in the basal diet; the meat quality improving functional particles include an adsorption core layer, a fat-soluble isolation layer covering the outside of the adsorption core layer, and a cross-linking protective layer covering the outside of the fat-soluble isolation layer; in this invention, the meat quality improving functional particles adopt a layered structure in which the adsorption core layer, the fat-soluble isolation layer, and the cross-linking protective layer are sequentially coated, and sodium dimethylglycinate and tea polyphenols are pre-loaded in the adsorption core layer formed by montmorillonite, so that the water-soluble functional components, which are originally prone to local distribution differences with the flow of materials, can enter the basal diet in particle form, which is convenient for uniform dispersion in a large batch of feed raw materials.

The present disclosure generally relates to a composition for use in a therapeutic method of treatment or prevention of a retinal disease or retinal impairment, said composition comprising: A) carnitine, deoxycarnitine, acetyl-L-carnitine, gamma-butyrobetaine, 4- trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6- trimethyl-L-lysine and / or lysine, preferably carnitine, such as L-carnitine; B) nicotinamide, nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D- ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, and / or nicotinate; C) optionally serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and / or phosphoserine, preferably serine or glycine; and D) optionally N-acetyl cysteine, cysteine and / or cystine.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, dimethylglycine, tryptophan, indoxylsulfate, phenylacetylglutamine, sialic acid, 5-hydroxy-6-indolyl-o-sulfate, 5-(Δ-carboxybutyl) homocysteine, and / or an anion having m / z:RMT:polarity of 345.1553:0.770:n, or determination of metabolites in stool samples, such as ketodeoxycholic acid, cholic acid, choline, tryptophan, trimethyllysine, serine, butyric acid, lactic acid, hypoxanthine and / or guanine.

The application provides a preparation method of deuterated betaine, and relates to the technical field of betaine. In suitable alkaline conditions, the positive methyl in deuterated iodomethane attacks the nitrogen atom containing a lone pair of electrons in N,N-dimethyl glycine to form a quaternary amine nitrogen to generate deuterated betaine. Then, the pH is adjusted to be neutral to remove sodium salt, and then impurities are effectively removed through a predetermined washing liquid. The method is simple to operate and convenient, and does not need recrystallization. Then, the pH is adjusted to be weakly acidic, so that deuterated betaine hydrochloride is not generated, deuterated betaine can be effectively separated, impurities are further removed, the yield of the product is high, and the separation is simple.

The invention discloses a urine metabolism marker composition for diagnosing kidney cancer and application of the urine metabolism marker composition, and relates to the technical field of biomedicine. The urine metabolism marker composition for diagnosing the kidney cancer is prepared from aspartic acid, N, N-dimethylglycine and 7-methyluric acid. The urine metabolism marker composition provided by the invention has relatively high sensitivity and specificity and relatively high accuracy when being used for diagnosing kidney cancer. Meanwhile, when the urine metabolism marker composition is used for kidney cancer diagnosis, operation is easy, a sample is convenient to obtain, cost is low, non-invasive performance is achieved, and the urine metabolism marker composition is more suitable for large-scale crowd screening and regular tracking in areas with shortage of medical resources. Besides, by detecting the urine metabolism marker composition provided by the invention in a urine sample, whether a patient suffers from the kidney benign disease or the kidney cancer can be judged only through one-time detection, so that excessive examination of the patient suffering from the kidney benign disease can be avoided, excessive diagnosis and treatment can be reduced, and excessive panic of the patient can be avoided.

The invention discloses an apigenin betaine compound and a preparation method thereof. According to the compound, apigenin (Api) is taken as a parent nucleus, hydroxyl groups at the 7 position, the 4'position and / or the 5 position of the apigenin (Api) are substituted by-O-(CH2) n-N + (CH3) 2-CH2COO-fragments (n is equal to 2-12, and x is equal to 1-3), so that an inner salt type zwitterionic structure is formed. The preparation method comprises the following steps: firstly, carrying out Mitsunobu reaction on apigenin and brominated alcohol Br (CH2) nOH under the condition of triphenylphosphine / dialkyl azodicarboxylate to obtain mono / polysubstituted bromine-containing alkoxy apigenin; and then carrying out nucleophilic substitution with N, N-dimethylglycine under an alkaline condition to obtain a target product. The structure has an adjustable alkyl chain and a betaine cation / anion pair, the solubility and hydration capacity of apigenin in a water / alcohol medium are remarkably improved, and the affinity and stability of apigenin to a biological membrane are enhanced, so that in-vivo absorption and distribution are improved, and the activities of oxidation resistance, inflammation resistance and the like of apigenin are expected to be maintained. The method is mild in condition, wide in solvent and temperature range and suitable for amplification and preparation application.

This invention discloses a biomarker combination for glioma risk screening or auxiliary diagnosis and its application. The biomarker combination comprises creatine, lactate, succinic acid, N,N-dimethylglycine, 2-oxoglutarate, acetic acid, and glutamate. Based on the biomarker combination provided by this invention, a clinical diagnostic model for assessing glioma risk can be constructed using algorithms such as multivariate logistic regression. The constructed clinical diagnostic model has high sensitivity and specificity, and can quickly and accurately assess the glioma risk of subjects, making it suitable for early screening and auxiliary diagnosis of adult gliomas.

The present invention relates to a composition comprising phosphinic acid or a salt thereof and dimethylglycine or a salt thereof, in particular in a dosage form for oral or topical administration. Furthermore, the present invention relates to the (cosmetic and / or medical) use of this composition for improving the condition of the hair and / or skin, promoting hair and / or skin metabolism, promoting hair growth, and / or treating and / or preventing hair loss. Furthermore, the present invention relates to a dietary supplement for promoting hair and / or skin metabolism and / or promoting hair growth and / or treating and / or preventing hair loss.Furthermore, the invention relates to a kit comprising dimethylglycine and / or a salt of dimethylglycine and phosphinic acid and / or at least one salt of phosphinic acid, wherein the two compounds are present in separate administration forms.